指南与共识产科母胎医学

儿童青少年及年轻女性癌症幸存者产科风险咨询与监测指南

Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adult cancer survivors: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
指南 / 共识 · Am J Obstet Gynecol · 2020-06-02

国际儿童癌症远期效应指南协调组基于1990-2018年系统检索证据,采用GRADE方法制定推荐,建议所有育龄女性癌症幸存者在孕前讨论治疗暴露相关产科风险,子宫放疗暴露者应接受高危产科监测。

要点

  • 所有育龄女性癌症幸存者孕前应基于癌症治疗暴露讨论不良产科结局风险。
  • 无证据支持幸存者子代先天畸形风险增加(高质量证据)。
  • 子宫暴露于放疗者应警惕流产、早产和低出生体重风险并接受高危产科监测。

核心结论

  • 女性儿童青少年及年轻癌症幸存者不良妊娠结局风险与癌症或治疗相关后遗症有关,应基于治疗暴露进行孕前咨询和高危产科监测。

主要发现

  • 无证据支持幸存者生育先天异常子代风险增加(高质量证据)。
  • 子宫暴露于放疗的幸存者流产风险增加(中等质量证据)。
  • 子宫暴露于放疗的幸存者早产风险增加(高质量证据)。
  • 子宫暴露于放疗的幸存者低出生体重风险增加(高质量证据)。
  • 接受蒽环类药物和胸部放疗的幸存者孕前或孕早期进行心肌病监测是合理的。

关键数值与推荐

  • 医疗提供者应在所有育龄女性儿童青少年及年轻癌症幸存者孕前讨论基于癌症治疗暴露的不良产科结局风险。
  • 子宫暴露于放疗的幸存者应接受高危产科监测。
  • 接受蒽环类药物和胸部放疗的所有女性幸存者孕前或孕早期心肌病监测是合理的。

临床怎么用

  • 对育龄女性癌症幸存者进行孕前咨询时,应结合其癌症治疗暴露(特别是子宫放疗、蒽环类药物和胸部放疗)评估产科风险。
  • 对子宫暴露于放疗的幸存者,应告知流产、早产和低出生体重风险并推荐高危产科监测。
  • 对接受蒽环类药物和胸部放疗的幸存者,考虑孕前或孕早期进行心肌病监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Female childhood, adolescent, and young adult cancer survivors have an increased risk of adverse pregnancy outcomes related to their cancer- or treatment-associated sequelae. Optimal care for childhood, adolescent, and young adult cancer survivors can be facilitated by clinical practice guidelines that identify specific adverse pregnancy outcomes and the clinical characteristics of at-risk subgroups. However, national guidelines are scarce and vary in content. Here, the International Late Effects of Childhood Cancer Guideline Harmonization Group offers recommendations for the counseling and surveillance of obstetrical risks of childhood, adolescent, and young adult survivors. A systematic literature search in MEDLINE database (through PubMed) to identify all available evidence published between January 1990 and December 2018. Published articles on pregnancy and perinatal or congenital risks in female cancer survivors were screened for eligibility. Study designs with a sample size larger than 40 pregnancies in childhood, adolescent, and young adult cancer survivors (diagnosed before the age of 25 years, not pregnant at that time) were eligible. This guideline from the International Late Effects of Childhood Cancer Guideline Harmonization Group systematically appraised the quality of available evidence for adverse obstetrical outcomes in childhood, adolescent, and young adult cancer survivors using Grading of Recommendations Assessment, Development, and Evaluation methodology and formulated recommendations to enhance evidence-based obstetrical care and preconception counseling of female childhood, adolescent, and young adult cancer survivors. Healthcare providers should discuss the risk of adverse obstetrical outcomes based on cancer treatment exposures with all female childhood, adolescent, and young adult cancer survivors of reproductive age, before conception. Healthcare providers should be aware that there is no evidence to support an increased risk of giving birth to a child with congenital anomalies (high-quality evidence). Survivors treated with radiotherapy to volumes exposing the uterus and their healthcare providers should be aware of the risk of adverse obstetrical outcomes such as miscarriage (moderate-quality evidence), premature birth (high-quality evidence), and low birthweight (high-quality evidence); therefore, high-risk obstetrical surveillance is recommended. Cardiomyopathy surveillance is reasonable before pregnancy or in the first trimester for all female survivors treated with anthracyclines and chest radiation. Female cancer survivors have increased risks of premature delivery and low birthweight associated with radiotherapy targeting the lower body and thereby exposing the uterus, which warrant high-risk pregnancy surveillance.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. van der Kooi ALF, Mulder RL, Hudson MM, et al. Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adult cancer survivors: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Am J Obstet Gynecol. 2020. PMID: 32502557. doi:10.1016/j.ajog.2020.05.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。